Eprosartan MesylateCAS# 144143-96-4 |
- MG-115
Catalog No.:BCC1237
CAS No.:133407-86-0
- Clasto-Lactacystin β-lactone
Catalog No.:BCC1224
CAS No.:154226-60-5
- PSI
Catalog No.:BCC1124
CAS No.:158442-41-2
- Salinosporamide A (NPI-0052, Marizomib)
Catalog No.:BCC2094
CAS No.:437742-34-2
- Gliotoxin
Catalog No.:BCN3894
CAS No.:67-99-2
- AM 114
Catalog No.:BCC3589
CAS No.:856849-35-9
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 144143-96-4 | SDF | Download SDF |
| PubChem ID | 5282474 | Appearance | Powder |
| Formula | C24H28N2O7S2 | M.Wt | 520.62 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 48 mg/mL (92.20 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 4-[[2-butyl-5-[(E)-2-carboxy-3-thiophen-2-ylprop-1-enyl]imidazol-1-yl]methyl]benzoic acid;methanesulfonic acid | ||
| SMILES | CCCCC1=NC=C(N1CC2=CC=C(C=C2)C(=O)O)C=C(CC3=CC=CS3)C(=O)O.CS(=O)(=O)O | ||
| Standard InChIKey | DJSLTDBPKHORNY-XMMWENQYSA-N | ||
| Standard InChI | InChI=1S/C23H24N2O4S.CH4O3S/c1-2-3-6-21-24-14-19(12-18(23(28)29)13-20-5-4-11-30-20)25(21)15-16-7-9-17(10-8-16)22(26)27;1-5(2,3)4/h4-5,7-12,14H,2-3,6,13,15H2,1H3,(H,26,27)(H,28,29);1H3,(H,2,3,4)/b18-12+; | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Potent angiotensin II receptor 1 (AT1) antagonist (IC50 values are 1.5, 1.7, 3.9 and 9.2 nM at rat mesenteric artery, human liver membrane, human adrenal cortical membrne and rat adrenal cortical membrane respectively). Displays no effect on vasopressin or CGRP binding, or angiotensin-converting enzyme (ACE) activity. Inhibits the angiotensin II-induced pressor response in normotensive rats. |
Eprosartan Mesylate Dilution Calculator
Eprosartan Mesylate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.9208 mL | 9.6039 mL | 19.2079 mL | 38.4157 mL | 48.0197 mL |
| 5 mM | 0.3842 mL | 1.9208 mL | 3.8416 mL | 7.6831 mL | 9.6039 mL |
| 10 mM | 0.1921 mL | 0.9604 mL | 1.9208 mL | 3.8416 mL | 4.802 mL |
| 50 mM | 0.0384 mL | 0.1921 mL | 0.3842 mL | 0.7683 mL | 0.9604 mL |
| 100 mM | 0.0192 mL | 0.096 mL | 0.1921 mL | 0.3842 mL | 0.4802 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Eprosartan is a nonpeptide angiotensin II receptor antagonist with IC50 of 9.2 and 3.9 nM in rat and human adrenal cortical membranes, respectively.
- Fmoc-Glu-OAll
Catalog No.:BCC3490
CAS No.:144120-54-7
- Fmoc-Asp-OAll
Catalog No.:BCC3086
CAS No.:144120-53-6
- Tarasaponin VII
Catalog No.:BCN2684
CAS No.:144118-18-3
- Deltarasin hydrochloride
Catalog No.:BCC4270
CAS No.:1440898-82-7
- Deltarasin
Catalog No.:BCC1524
CAS No.:1440898-61-2
- Febuxostat
Catalog No.:BCC2556
CAS No.:144060-53-7
- 6-O-Syringoylajugol
Catalog No.:BCN6246
CAS No.:144049-72-9
- Piclamilast
Catalog No.:BCC6215
CAS No.:144035-83-6
- BRD73954
Catalog No.:BCC5652
CAS No.:1440209-96-0
- Sodium Nitroprusside
Catalog No.:BCC4844
CAS No.:14402-89-2
- Sulfapyridine
Catalog No.:BCC4729
CAS No.:144-83-2
- Sulfamethizole
Catalog No.:BCC4856
CAS No.:144-82-1
- Ledipasvir acetone
Catalog No.:BCC4046
CAS No.:1441674-54-9
- Indoxacarb
Catalog No.:BCN2263
CAS No.:144171-61-9
- 1-Acetyl-4-methylpiperazine hydrochloride
Catalog No.:BCC6615
CAS No.:144205-68-5
- YYA-021
Catalog No.:BCC5346
CAS No.:144217-65-2
- Dehydroadynerigenin glucosyldigitaloside
Catalog No.:BCN1568
CAS No.:144223-70-1
- ML 337
Catalog No.:BCC6345
CAS No.:1443118-44-2
- 1-Deazaadenosine
Catalog No.:BCC6204
CAS No.:14432-09-8
- Trilepisflavan
Catalog No.:BCN6786
CAS No.:1443218-16-3
- YM 26734
Catalog No.:BCC7396
CAS No.:144337-18-8
- Nemoralisin C
Catalog No.:BCN7680
CAS No.:1443421-84-8
- CCG 203971
Catalog No.:BCC5601
CAS No.:1443437-74-8
- GSK2838232
Catalog No.:BCC6372
CAS No.:1443461-21-9
Development and Validation of a UV Spectrophotometric Method for the Simultaneous Estimation of Eprosartan Mesylate and Hydrochlorothiazide in Bulk and Formulations.[Pubmed:22923871]
Indian J Pharm Sci. 2011 Sep;73(5):569-72.
A simple, efficient, precise and accurate absorbance ratio method have been developed for the estimation of Eprosartan Mesylate and hydrochlorothiazide in pure and in fixed dose combination. In this method, UV spectra of Eprosartan Mesylate and hydrochlorothiazide were overlayed which involves the formation of Q-absorbance equation at 249.1 nm (isobestic point) and 274.5 nm, the max of hydrochlorothiazide. Both the drugs obeyed Beers law in the concentration range of 6-36 mug/ml and 1-10 mug/ml for Eprosartan Mesylate and hydrochlorothiazide, respectively. The accuracy of the method was determined by recovery studies and was found to be in the range of 102.29-103.10% and 99.52-101.60% for Eprosartan Mesylate and hydrochlorothiazide, respectively. The method was validated as per ICH guidelines and statistically. The method showed good reproducibility and recovery with % RSD less than 2. The method was found to be simple, economic, accurate and reproducible and can be used for routine analysis of Eprosartan Mesylate and hydrochlorothiazide in pure and in fixed dose combinations.
Formulation and statistical optimization of self-microemulsifying drug delivery system of eprosartan mesylate for improvement of oral bioavailability.[Pubmed:27465619]
Drug Deliv Transl Res. 2016 Oct;6(5):610-21.
The present investigation is aimed to design a statistically optimized self-microemulsifying drug delivery system (SMEDDS) of Eprosartan Mesylate (EM). Preliminary screening was carried out to find a suitable combination of various excipients for the formulation. A 3(2) full factorial design was employed to determine the effect of various independent variables on dependent (response) variables. The independent variables studied in the present work were concentration of oil (X 1) and the ratio of S mix (X 2), whereas the dependent variables were emulsification time (s), globule size (nm), polydispersity index (pdi), and zeta potential (mV), and the multiple linear regression analysis (MLRA) was employed to understand the influence of independent variables on dependent variables. Furthermore, a numerical optimization technique using the desirability function was used to develop a new optimized formulation with desired values of dependent variables. The optimized SMEDDS formulation of Eprosartan Mesylate (EMF-O) by the above method exhibited emulsification time, 118.45 +/- 1.64 s; globule size, 196.81 +/- 1.29 nm; zeta potential, -9.34 +/- 1.2 mV, and polydispersity index, 0.354 +/- 0.02. For the in vitro dissolution study, the optimized formulation (EMF-O) and pure drug were separately entrapped in the dialysis bag, and the study indicated higher release of the drug from EMF-O. In vivo pharmacokinetic studies in Wistar rats using PK solver software revealed 2.1-fold increment in oral bioavailability of EM from EMF-O, when compared with plain suspension of pure drug.
Quality by design: a systematic and rapid liquid chromatography and mass spectrometry method for eprosartan mesylate and its related impurities using a superficially porous particle column.[Pubmed:24913516]
J Sep Sci. 2014 Aug;37(16):2160-71.
The present work describes the systematic development of a robust, precise, and rapid reversed-phase liquid chromatography method for the simultaneous determination of Eprosartan Mesylate and its six impurities using quality-by-design principles. The method was developed in two phases, screening and optimization. During the screening phase, the most suitable stationary phase, organic modifier, and pH were identified. The optimization was performed for secondary influential parameters--column temperature, gradient time, and flow rate using eight experiments--to examine multifactorial effects of parameters on the critical resolution and generated design space representing the robust region. A verification experiment was performed within the working design space and the model was found to be accurate. This study also describes other operating features of the column packed with superficially porous particles that allow very fast separations at pressures available in most liquid chromatography instruments. Successful chromatographic separation was achieved in less than 7 min using a fused-core C18 (100 mm x 2.1 mm, 2.6 mum) column with linear gradient elution of 10 mM ammonium formate (pH 3.0) and acetonitrile as the mobile phase. The method was validated for specificity, linearity, accuracy, precision, and robustness in compliance with the International Conference on Harmonization Q2 (R1) guidelines. The impurities were identified by liquid chromatography with mass spectrometry.
Pharmacodynamic study of eprosartan mesylate-loaded transfersomes Carbopol((R)) gel under Dermaroller((R)) on rats with methyl prednisolone acetate-induced hypertension.[Pubmed:28237913]
Biomed Pharmacother. 2017 May;89:177-184.
The objective of present study was to prepare Eprosartan Mesylate (EM)-loaded transfersomes Carbopol((R)) gel and characterized for various parameters, including in vitro skin permeation, in vivo antihypertensive study, skin irritation, and histological study. Furthermore, effect of transfersomes gel on angiotensin II type-1 receptor (AT1R) mRNA and protein expressions on smooth vascular muscles of aorta was determined by real-time polymerase chain reaction (RT-PCR) and western blot analysis. The physical evaluation parameters were detected to be in correspondence with reference marketed gel formulation. The transdermal flux, permeability coefficient, and Tlag of EM from transfersomes gel were found to be 26.76 +/- 1.66mug/cm(2)/h, 8.93 +/- 0.55 x10(-3) cm/h, and 2.17 +/- 0.29h, respectively, across rat skin pretreated with microneedle (Dermaroller((R))). Pharmacodynamic study showed prolonged and better management of hypertension after the application of transfersomes gel in experimentally induced hypertensive Wistar rats as compared with oral control formulation. The in vivo angiotensin II type-1 blocking efficacy of prepared transfersomes gel and control formulation was also supported with RT-PCR and western blot analysis of AT1R mRNA and protein expressions on smooth vascular muscles of aorta. Skin irritation and skin histological assessment showed that the prepared transfersomes Carbopol((R)) gel was safe to be used for transdermal route. It is concluded that the incorporation of transfersomes into gel formulation offered enhanced skin contact, ease of application, and found to be a suitable drug reservoir for the transdermal delivery of EM for the management of hypertension in Wistar rats.
